DEFB122: A Potential Drug Target and Biomarker (G245935)

Target Name: DEFB122

NCBI ID: G245935

DEFB122

Other Name(s): DEFB-22 | DEFB22 | defensin beta 122 (pseudogene) | Defensin, beta 122 (pseudogene) | DEFB122P

DEFB122: A Potential Drug Target and Biomarker

DEFB122 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the development and maintenance of tissues, including the nervous system. Based on this information, DEFB122 may be a drug target or biomarker that can be targeted by small molecules.

The search for drug targets and biomarkers is a crucial aspect of modern medicine. Drug targets are proteins that are involved in the development and progression of diseases, while biomarkers are proteins or other molecules that can be used as indicators of disease status. The identification of potential drug targets and biomarkers is a critical step in the development of new treatments for a variety of diseases.

Current Theories

The function of DEFB122 is not well understood, but it is known to be involved in the development and maintenance of tissues. This suggests that it may be a potential drug target or biomarker. One possible mechanism by which DEFB122 may be involved in the development of certain diseases is by contributing to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Additionally, DEFB122 has been shown to be involved in the development and progression of certain diseases, such as cancer. This suggests that it may be a potential biomarker for cancer, and that its levels may be useful as a diagnostic marker.

Potential Applications

The identification of potential drug targets and biomarkers is an exciting area of research, with the potential to lead to the development of new treatments for a variety of diseases. The potential applications of DEFB122 as a drug target or biomarker are vast and varied.

In the context of neurodegenerative diseases, DEFB122 may be a potential drug target by which to treat the symptoms of these conditions. For example, by targeting DEFB122, researchers may be able to develop new treatments for Alzheimer's disease and other neurodegenerative conditions.

In the context of cancer, DEFB122 may be a potential biomarker for the disease. By measuring the levels of DEFB122 in cancer cells, researchers may be able to identify those cells that are resistant to treatment, which could help to inform the development of new treatments for cancer.

Conclusion

In conclusion, DEFB122 is a protein that is expressed in various tissues of the body and is involved in the development and maintenance of tissues. Its function is not well understood, but it may be a potential drug target or biomarker. Further research is needed to fully understand its role in the development and progression of diseases.

Protein Name: Defensin Beta 122 (pseudogene)

The "DEFB122 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB122 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets